In this application, we propose to establish an integrated proteome characterization center (PCC) with an outstanding team of scientists and clinicians in order to construct a cancer biomarker pipeline using genoproteomic approaches. This multidisciplinary team consists of internationally recognized experts in clinical oncology, clinical chemistry, cancer biology, proteomic technologies, proteomics/genomics-specific bioinformatics, biostatistics and experimental design, metrology/standards, technology optimization, assay construction, project management and patient advocacy. The plan is to connect genomics with proteomics (genoproteomics). We believe that genomic data provides a highly valuable molecular route towards the identification of genes and pathways that could be useful for the detection, differential diagnosis, outcome prediction and therapeutic targets of cancer. The proteomic approaches will provide the identification of unique features that are inherent to proteins including post-translational modifications, such as glycosylation and phosphorylation. We propose a two- step strategy to construct an evidence-based, proteomic biomarker pipeline for ovarian and other carcinomas. The first step is the discovery of candidate biomarkers from genomic data including TCGA using mass spectrometry and affinity based technologies on human specimens. The goal is to comprehensively characterize tumor and normal biospecimens and identify their protein composition in order to systematically identify and prioritize cancer-related proteins for advancement to verification. The second step is the verification of these candidates using targeted assays. The goal is to generate accurate, reproducible, sensitive, quantitative, multiplex assays using optimized and standardized high-throughput technologies for the discovered biomarkers. While this application is not intended to conduct large scale clinical studies, we believe that the ultimate clinical application and the performance characteristics of these assays should be clearly defined. With this multidisciplinary team of outstanding scientists and clinicians, our PCC offers the best opportunity for the success of biomarker discovery and verification for personalized cancer medicine.

Public Health Relevance

Understanding the molecular networking in carcinogenesis is essential for the development of a successful strategy to reduce cancer mortality. Based on the genomic alterations identified from TCGA and other sources, this application will focus on the development of a clinically useful protein biomarker pipeline using state-of-the art proteomics technologies for personalized cancer medicine.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Resource-Related Research Projects--Cooperative Agreements (U24)
Project #
5U24CA160036-05
Application #
8904624
Study Section
Special Emphasis Panel (ZCA1-SRLB-R (J1))
Program Officer
Hiltke, Tara
Project Start
2011-08-29
Project End
2016-07-31
Budget Start
2015-08-01
Budget End
2016-07-31
Support Year
5
Fiscal Year
2015
Total Cost
$1,859,557
Indirect Cost
$531,856
Name
Johns Hopkins University
Department
Pathology
Type
Schools of Medicine
DUNS #
001910777
City
Baltimore
State
MD
Country
United States
Zip Code
21205
Solanki, Hitendra S; Raja, Remya; Zhavoronkov, Alex et al. (2018) Targeting focal adhesion kinase overcomes erlotinib resistance in smoke induced lung cancer by altering phosphorylation of epidermal growth factor receptor. Oncoscience 5:21-38
Höti, Naseruddin; Yang, Shuang; Hu, Yingwei et al. (2018) Overexpression of ? (1,6) fucosyltransferase in the development of castration-resistant prostate cancer cells. Prostate Cancer Prostatic Dis 21:137-146
Yu, Kun-Hsing; Hart, Steven N; Goldfeder, Rachel et al. (2017) HARNESSING BIG DATA FOR PRECISION MEDICINE: INFRASTRUCTURES AND APPLICATIONS. Pac Symp Biocomput 22:635-639
Yu, Kun-Hsing; Berry, Gerald J; Rubin, Daniel L et al. (2017) Association of Omics Features with Histopathology Patterns in Lung Adenocarcinoma. Cell Syst 5:620-627.e3
Thomas, Stefani N; Chen, Lijun; Liu, Yang et al. (2017) Targeted Proteomic Analyses of Histone H4 Acetylation Changes Associated with Homologous-Recombination-Deficient High-Grade Serous Ovarian Carcinomas. J Proteome Res 16:3704-3710
Huang, Yi; Zhu, Heng (2017) Protein Array-based Approaches for Biomarker Discovery in Cancer. Genomics Proteomics Bioinformatics 15:73-81
Höti, Naseruddin; Shah, Punit; Hu, Yingwei et al. (2017) Proteomics analyses of prostate cancer cells reveal cellular pathways associated with androgen resistance. Proteomics 17:
Pan, Jianbo; Song, Guang; Chen, Dunyan et al. (2017) Identification of Serological Biomarkers for Early Diagnosis of Lung Cancer Using a Protein Array-Based Approach. Mol Cell Proteomics 16:2069-2078
Nie, Litong; Shuai, Lin; Zhu, Mingrui et al. (2017) The Landscape of Histone Modifications in a High-Fat Diet-Induced Obese (DIO) Mouse Model. Mol Cell Proteomics 16:1324-1334
Zhou, Jian-Ying; Chen, Lijun; Zhang, Bai et al. (2017) Quality Assessments of Long-Term Quantitative Proteomic Analysis of Breast Cancer Xenograft Tissues. J Proteome Res 16:4523-4530

Showing the most recent 10 out of 165 publications